Mosley Wealth Management Makes New Investment in AbbVie Inc. $ABBV

Mosley Wealth Management purchased a new position in shares of AbbVie Inc. (NYSE:ABBV) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 2,364 shares of the company’s stock, valued at approximately $547,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Founders Financial Alliance LLC raised its holdings in AbbVie by 0.5% during the 4th quarter. Founders Financial Alliance LLC now owns 18,435 shares of the company’s stock worth $4,212,000 after purchasing an additional 90 shares during the last quarter. Sustainable Insight Capital Management LLC raised its holdings in AbbVie by 247.0% during the 4th quarter. Sustainable Insight Capital Management LLC now owns 3,512 shares of the company’s stock worth $802,000 after purchasing an additional 2,500 shares during the last quarter. RKL Wealth Management LLC raised its holdings in AbbVie by 8.1% during the 4th quarter. RKL Wealth Management LLC now owns 17,748 shares of the company’s stock worth $4,055,000 after purchasing an additional 1,328 shares during the last quarter. Investment Research Partners LLC grew its position in shares of AbbVie by 5.3% during the 4th quarter. Investment Research Partners LLC now owns 5,109 shares of the company’s stock worth $1,168,000 after buying an additional 258 shares during the period. Finally, Woodley Farra Manion Portfolio Management Inc. grew its position in shares of AbbVie by 57.3% during the 4th quarter. Woodley Farra Manion Portfolio Management Inc. now owns 23,199 shares of the company’s stock worth $5,301,000 after buying an additional 8,453 shares during the period. Institutional investors own 70.23% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts and media coverage highlighted AbbVie’s Skyrizi and Rinvoq as key growth drivers, noting strong first-quarter performance and the potential for continued sales momentum through 2026, including additional indications. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Positive Sentiment: Another market commentary framed AbbVie as a growth-pharma stock at a value-pharma price, reinforcing the view that its earnings growth and pipeline may justify the valuation. AbbVie: Growth-Pharma Profile At A Value-Pharma Price
• Positive Sentiment: AbbVie was also featured on CNBC’s “Final Trades”, which can support investor sentiment by keeping the stock in the market spotlight. AbbVie, Devon Energy and more on CNBC’s ‘Final Trades’
• Neutral Sentiment: Several pieces described AbbVie as a stock worth watching or holding after a strong run, with valuation and balance-sheet concerns tempering enthusiasm but not signaling a major change in the business outlook. Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225
• Negative Sentiment: AbbVie also faced a FDA Complete Response Letter for its fast-acting neurotoxin TrenibotE, citing manufacturing-related issues. While the letter reportedly raised no safety or efficacy concerns, it delays the program and adds near-term regulatory uncertainty. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Trading Up 0.0%

NYSE ABBV opened at $225.04 on Friday. The company has a fifty day simple moving average of $210.80 and a 200 day simple moving average of $219.01. AbbVie Inc. has a 12-month low of $181.73 and a 12-month high of $244.81. The company has a market cap of $397.60 billion, a P/E ratio of 110.86, a PEG ratio of 0.69 and a beta of 0.32.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter last year, the firm posted $2.46 EPS. AbbVie’s revenue was up 12.4% compared to the same quarter last year. Sell-side analysts predict that AbbVie Inc. will post 14.3 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ABBV shares. Canaccord Genuity Group raised their price objective on shares of AbbVie from $262.00 to $265.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. DZ Bank raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Bank of America raised shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective for the company in a research report on Thursday, April 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research report on Monday. Finally, William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, AbbVie has an average rating of “Moderate Buy” and an average price target of $253.43.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.